Roche jumps into epigenetics with deal for Oryzon's leukemia hopeful

Roche Head of Pharmaceutical Research John Reed

John Reed's Basel-based pRED group at Roche ($RHHBY) has struck its first epigenetics deal with a $500 million-plus potential payoff for Barcelona-based Oryzon and its orphan cancer blocker ORY-1001, now being studied in the clinic for acute myeloid leukemia. Report